NASDAQ:KRBP Kiromic BioPharma (KRBP) Stock Forecast, Price & News $2.85 -0.15 (-5.00%) (As of 02:18 PM ET) Add Compare Share Share Today's Range$2.80▼$3.1550-Day Range$2.86▼$5.2252-Week Range$2.59▼$22.80Volume124,154 shsAverage Volume246,203 shsMarket Capitalization$2.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Kiromic BioPharma (NASDAQ:KRBP) StockKiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Read More Receive KRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address KRBP Stock News HeadlinesMay 18, 2023 | americanbankingnews.comCritical Analysis: Kiromic BioPharma (NASDAQ:KRBP) and Cullinan Oncology (NASDAQ:CGEM)May 14, 2023 | americanbankingnews.comShort Interest in Kiromic BioPharma, Inc. (NASDAQ:KRBP) Declines By 46.5%June 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 3, 2023 | finance.yahoo.comWhat's Going On With Kiromic BioPharma Stock WednesdayMay 1, 2023 | finance.yahoo.comKiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung CancerMay 1, 2023 | americanbankingnews.comKiromic BioPharma, Inc. (NASDAQ:KRBP) Short Interest Up 7.5% in AprilApril 3, 2023 | finance.yahoo.comKiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung CancerMarch 10, 2023 | finance.yahoo.comKiromic BioPharma Announces Reverse Stock SplitJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. February 28, 2023 | finance.yahoo.comKiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology ResultsFebruary 23, 2023 | finance.yahoo.comTwo Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote "FOR" All Proxy ProposalsFebruary 16, 2023 | msn.comKiromic BioPharma CEO encourages stock split, sees Deltacel trial in 2Q23February 16, 2023 | finance.yahoo.comKiromic BioPharma CEO Issues Letter to StockholdersJanuary 15, 2023 | yahoo.comCambrian BioPharma Unveils New Pipeline Company - Isterian BiotechJanuary 15, 2023 | seekingalpha.comCTI BioPharma: Checking Back InOctober 27, 2022 | finance.yahoo.comKiromic BioPharma Arranges Up to $10 Million FinancingOctober 14, 2022 | finance.yahoo.comKiromic Shares Surge After Streamlining Operations To Execute Deltacel-Aligned Development StrategyOctober 6, 2022 | finance.yahoo.comKiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development StrategyOctober 6, 2022 | marketwatch.comHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class ActionOctober 5, 2022 | stockhouse.comDEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the FirmOctober 5, 2022 | theglobeandmail.comKiromic BioPharma: Top 10 Undervalued Healthcare Stocks on NAS (KRBP)October 4, 2022 | benzinga.comFINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the FirmOctober 4, 2022 | benzinga.comHagens Berman, National Trial Attorneys, Announces It Has Filed A Class Action Lawsuit Against Kiromic BioPharma (KRBP)October 3, 2022 | benzinga.comFinal Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively ParticipateOctober 2, 2022 | prnewswire.comKRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action LawsuitOctober 1, 2022 | benzinga.comDeadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kiromic BioPharma, Inc. (KRBP) Investors of Filing Deadline in Class Action LawsuitSeptember 24, 2022 | prnewswire.comKRBP DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important October 4, 2022 Deadline Reminder for Kiromic BioPharma, Inc.See More Headlines KRBP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRBP Company Calendar Today6/02/2023Next Earnings (Estimated)6/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRBP CUSIPN/A CIK1792581 Webwww.kiromic.com Phone832-968-4888FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($30.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-475.16% Return on Assets-202.73% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($8.31) per share Price / Book-0.36Miscellaneous Outstanding Shares980,000Free Float907,000Market Cap$2.94 million OptionableNot Optionable Beta0.17 Key ExecutivesMr. Pietro Bersani CPA (Age 55)J.D., CEO & Director Comp: $167.76kDr. Scott Dahlbeck M.D. (Age 61)Pharm.D., PharmD, Chief of Staff Comp: $442.12kMr. Daniel Clark (Age 34)Chief Financial Officer Dr. Leonardo Mirandola Ph.D.Chief Scientific OfficerDr. Michael Ryan Ph.D. (Age 56)Chief Bioinformatics Research Computing Officer Key CompetitorsFresh Tracks TherapeuticsNASDAQ:FRTXBiondVax PharmaceuticalsNASDAQ:BVXVBrookline Capital AcquisitionNASDAQ:BCACPolarityTENASDAQ:PTERubius TherapeuticsNASDAQ:RUBYView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 16,457 shares on 5/16/2023Ownership: 1.681%View All Institutional Transactions KRBP Stock - Frequently Asked Questions How have KRBP shares performed in 2023? Kiromic BioPharma's stock was trading at $5.4210 at the start of the year. Since then, KRBP stock has decreased by 44.7% and is now trading at $3.00. View the best growth stocks for 2023 here. When is Kiromic BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 2nd 2023. View our KRBP earnings forecast. When did Kiromic BioPharma's stock split? Shares of Kiromic BioPharma reverse split before market open on Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Kiromic BioPharma IPO? (KRBP) raised $16 million in an IPO on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager. What is Kiromic BioPharma's stock symbol? Kiromic BioPharma trades on the NASDAQ under the ticker symbol "KRBP." Who are Kiromic BioPharma's major shareholders? Kiromic BioPharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Susquehanna International Group LLP (1.68%). Insiders that own company stock include Internati Maurizio Chiriva and Jerry A Schneider. View institutional ownership trends. How do I buy shares of Kiromic BioPharma? Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kiromic BioPharma's stock price today? One share of KRBP stock can currently be purchased for approximately $3.00. How much money does Kiromic BioPharma make? Kiromic BioPharma (NASDAQ:KRBP) has a market capitalization of $2.94 million. The company earns $-34,730,000.00 in net income (profit) each year or ($30.33) on an earnings per share basis. How can I contact Kiromic BioPharma? The official website for the company is www.kiromic.com. The company can be reached via phone at 832-968-4888 or via email at bus.dev@kiromic.com. This page (NASDAQ:KRBP) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.